Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Krka Group
Krka Talks Russia, Ukraine, One Year After Conflict Began
Slovenia’s Krka enjoyed a solid year for its dominant Prescription Pharmaceuticals business, with sales climbing by 7% on the back of growth for all six of its geographic business units.
Who’s Hired? Nichi-Iko Looks To Sandoz For Fresh Leadership
Nichi-Iko has revealed its choice of new leadership, looking to Sandoz Japan for its next president and CEO. Meanwhile, Ethypharm and Krka have made fresh appointments in the UK and Centrient has named a new chief quality officer.
Krka Underlines Message On Entering Biosimilars Arena In Europe
Krka’s management discussed the firm’s latest perception of the European biosimilars market, as it reported financial results for the nine months to 30 September.
Krka’s EBITDA Margin Slumps Despite Record H1 Sales
Krka has explained a near double-digit percentage point drop for its EBITDA margin, as it presented preliminary results for the first half of 2022.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Krka DD, Krka d.d., Krka Pharmaceuticals
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.